Merus NV at Needham Healthcare Conference (Virtual) Transcript
Good morning, everyone, again. This is Ami Fadia; I cover neuroscience and targeted oncology at Needham. It's my pleasure to be hosting Merus for this next session, and we have with us Bill Lundberg who is the CEO of the company. (Conference Instructions) And with that let me kick it off.
Questions & Answers
Bill, Zeno is top of mind for everybody listening in. So, perhaps if you could start by giving us an update on where things stand with the Phase 1/2 trial. You're due to expect some data in the near future.
Happy to. And first let me say thank you to you and the entire Needham team and to the support staff for allowing us to participate. We really appreciate the opportunity to share where we are and progress to date. And also just a couple words about the company.
As many of you know, but perhaps not all, we're a
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |